Ipilimumab is also used in combination with nivolumab (anti-PD-1), which enhances both priming and tumor infiltration of activated T cells, resulting in improved survival outcomes in melanoma, RCC, and NSCLC [14,83,113]. Here, PDCD1 is linked to renal cell carcinoma.